How Many Units of Botox for TMJ? What Sets the Dose

There is no universally established or FDA-approved BOTOX dose for TMJ or temporomandibular disorders (TMD). The amount quoted can change with the toxin product, diagnosis, muscles selected, number of sides treated, and whether the figure refers to one muscle or the whole session. The FDA prescribing information for BOTOX Cosmetic provides no TMD dosing regimen.

The short answer: there is no standard number of units

This is a practical description of published practice estimates, not a clinical guideline or a dose recommendation for an individual.

A physician-authored clinic article describes 15–20 Units per side, or 30–40 Units total, as its typical approach. The page does not cite clinical trials or formal dosing guidance supporting that range, so it should be treated as the clinic’s practice estimate. See the clinic’s stated dosing approach.

Another commercial clinic describes 20–40 Units per masseter per side, with the amount selected partly according to muscle size and strength. That page also addresses cosmetic masseter reduction, so its range is not a dosing guideline for every cause of TMD. Review the clinic’s masseter dosing ranges.

The arithmetic is important:

• 20 Units in the left masseter + 20 Units in the right masseter = 40 Units total
• 40 Units in the left masseter + 40 Units in the right masseter = 80 Units total

It could mean 30 Units for the entire session, 30 Units on each side, or 30 Units in one muscle before other muscles are counted.

A complete proposal should identify:

• The exact botulinum toxin product
• The diagnosis and treatment goal
• Every muscle being targeted
• The amount for each muscle and each side
• The total number of Units for the session

Without those details, apparently different quotes may describe similar plans—or matching totals may describe substantially different treatments.

What published dosing examples actually show

Online estimates range widely because providers count Units in different ways. Some describe the amount per side, while others give only a session total. Some inject the masseters alone; others divide the total among the masseters and temporalis muscles.

Source and protocol	Units per side or muscle	Total Units	Evidence limitation
Cuthbertson physician-clinic estimate; primarily masseters, with temporalis sometimes considered	15–20 per side	30–40	Uncited clinic practice estimate, not a guideline
Plump commercial masseter estimate	20–40 per masseter	40–80 for two masseters	Also discusses cosmetic jaw slimming; not a TMD dosing guideline
Jackson Avenue Dental starting protocol; commonly allocated to the masseters	Usually 25 per masseter	50 initially; practice describes a 50–100 range	Commercial, uncited practice recommendation
Kahn and colleagues’ retrospective four-muscle protocol	30 per masseter and 20 per temporalis	100	Small, uncontrolled, single-center study

Jackson Avenue Dental describes 50 Units total, commonly divided into 25 Units in each masseter, as its first-time starting protocol. The practice presents 50–100 Units total as its broader range and says the masseter may be treated alone or with the temporalis. These are the practice’s recommendations, not independently established dosing rules. Read the dental practice’s protocol.

The research example used a different injection pattern. In a retrospective study with complete follow-up for 34 patients, the usual session contained 100 Units total: 30 Units in each masseter and 20 Units in each temporalis, distributed across 10 injection sites. The authors reported that there was no consensus on the optimal dose and said muscle mass and symptom severity could influence dosing. The study was small, retrospective, conducted at one center, and did not include a randomized placebo control. Examine the study protocol and limitations.

That four-muscle protocol cannot be compared directly with a 40- or 50-Unit masseter-only plan. The temporalis injections added 40 Units to the study’s session total. A meaningful comparison must account for the product, muscles, sides, and distribution—not just the final number.

The evidence also does not establish that the lowest or highest example is inherently better. These figures show how several clinics and one research group structured treatment; they do not define a universal standard.

The diagnosis and target muscles matter more than a single number

“TMJ” is often used as a general label for jaw symptoms, but the temporomandibular joint is an anatomical structure. TMD refers to a broader group of disorders involving the joint, the chewing muscles, or both. Saying that pain is “TMJ” does not establish whether it comes mainly from an overactive muscle or from a structure inside the joint.

That distinction matters because botulinum toxin acts on the muscles into which it is injected. It inhibits acetylcholine release at the neuromuscular junction, weakening muscle contraction. A clinical review of myofascial TMD identifies the masseter and temporalis as common muscular targets and notes that the lateral pterygoid may be involved in some symptom patterns. The review does not provide a standard dose for those muscles. See the review of botulinum toxin for myofascial TMD.

Before proposing an injection pattern, a clinician may consider:

• Whether the condition appears muscle-related, joint-related, or mixed
• Which muscles reproduce the person’s symptoms
• Whether one side or both sides are being considered
• Muscle bulk, strength, and asymmetry
• Symptom severity and functional limitations
• Previous response to botulinum toxin, if any
• Injection location, depth, and technique
• The exact toxin product being used

The treatment goal also changes how a quote should be interpreted. An injection plan intended to reduce muscular pain or clenching is not necessarily the same as one designed to narrow the lower face. Both may involve the masseter, but the desired outcomes and methods of evaluating success differ.

Weakening a chewing muscle also does not establish that pain arising primarily inside the jaw joint will improve. A clinician must first identify what is being treated; the unit count comes afterward.

BOTOX for TMD is off-label, and brand Units are not interchangeable

TMJ or TMD treatment is not among the indications listed in the FDA prescribing information for BOTOX Cosmetic. The labeled indications concern temporary cosmetic improvement of specific facial and neck lines, and the label provides doses tied to those particular muscles and purposes. Those cosmetic schedules should not be reused as guidance for jaw pain, clenching, bruxism, or TMD.

The label also states that BOTOX Units are specific to the product’s preparation and assay method. They cannot be directly compared with or converted into Units of Dysport, Xeomin, or another botulinum toxin product. Review the FDA prescribing information.

When comparing estimates, ask for the full product name. A quote containing more Units does not necessarily represent a larger or stronger treatment if it uses a different product with a different unit scale.

Too much muscle weakening can affect jaw function

The masseter and temporalis contribute to chewing and jaw movement. Excessive or unintended weakening may interfere with those functions.

Commercial practice materials cited above describe possible effects including:

• Chewing fatigue or difficulty managing food
• An altered bite sensation
• Speech or mouth-movement difficulty
• Weakness caused by unintended effects on nearby muscles

These statements come from the Plump clinic and Jackson Avenue Dental practice materials, not from an established complication-rate guideline. They explain why the proposed distribution and total matter, but they do not show how frequently each problem occurs.

The retrospective study summarized above also reported one transient case of facial paresis affecting the patient’s smile. A single event in a small, uncontrolled study cannot establish the overall likelihood of smile asymmetry or facial weakness.

The FDA boxed warning states that botulinum toxin effects may spread beyond the injection area. Reported effects include potentially life-threatening swallowing or breathing difficulty, with symptoms occurring hours to weeks after injection. The label also lists hypersensitivity to botulinum toxin preparations and infection at the proposed injection site as contraindications.

Seek urgent medical help if swallowing or breathing becomes difficult after an injection. Before treatment, discuss risks relevant to your medical history with the treating clinician rather than relying on a generic online list.

Where injections may fit in a TMD care plan

Botulinum toxin may be considered as an adjunct or later option for selected patients when appropriate conservative management has not provided sufficient relief. It is not a required next step for everyone with jaw pain, clenching, bruxism, or a TMD diagnosis.

The clinical review cited earlier describes initial management that may include:

• Avoiding movements, foods, or habits that trigger symptoms
• Temporarily adjusting food texture
• Appropriate pain management
• Physical therapy
• Warm compresses
• Evaluating whether an occlusal splint is appropriate when bruxism is present

The same review discusses botulinum toxin as an adjunct for patients who do not respond completely to conservative management and pharmacotherapy. The retrospective study likewise considered injections after non-invasive therapies had failed.

These sources do not establish that botulinum toxin is superior to a splint, physical therapy, medication, or another conservative approach. Nor do they show that injections are appropriate for every form of TMD.

The relevant options depend on the diagnosis. Someone with muscle-led pain and clenching may face a different decision from someone whose symptoms arise mainly from inflammation, injury, or structural disease within the joint. A useful consultation should explain why injections are being considered now, what alternatives remain, and what result would count as meaningful improvement.

Questions to ask before agreeing to a unit count

Use the consultation to clarify the plan rather than trying to select a dose online.

1. What diagnosis are you treating? Is the plan directed at myofascial TMD, bruxism, pain originating inside the joint, headache, or cosmetic masseter enlargement?

2. What exact product will you use? Ask for the brand and active product name rather than accepting “Botox” as a generic term.

3. Which muscles will be injected? Request a list of every target, including the right and left masseters, temporalis muscles, or any other proposed muscle.

4. How many Units will go into each muscle and each side? Confirm whether the quoted figure is per side, per muscle, per injection point, or for the whole session.

5. What is the total session dose? Add the amounts across all muscles and both sides so that the quote is unambiguous.

6. Why does this distribution fit the examination findings? The explanation should connect the injection pattern to the diagnosis, muscle activity, asymmetry, and treatment goal.

7. Why is bilateral treatment being proposed if symptoms are mainly on one side?

8. Which conservative measures have already been tried? Discuss how long they were used, what happened, and whether other reasonable options remain.

9. What evidence supports this protocol? Ask whether the number comes from a published study, formal guidance, the injector’s own practice pattern, or a cosmetic protocol.

10. How and when will the response be reassessed? Follow-up should evaluate pain, clenching, chewing strength, bite sensation, mouth movement, smile symmetry, and unwanted weakness—not only visible jaw shape.

11. What relevant training and experience does the injector have? Ask specifically about TMD assessment and facial and masticatory-muscle anatomy, not only general cosmetic-injection experience.

A proposed dose makes sense only when it identifies the product, diagnosis, target muscles, amount per side, and total session Units. The published figures are attributed educational examples from commercial practices and a small retrospective study. They cannot determine the dose—or whether injections are appropriate—for an individual.